Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
12 min read
Purpura, Thrombocytopenic Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
27 August 2026
Evaluate Purpura, Thrombocytopenic in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Nephrolithiasis Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
27 August 2026
Evaluate Nephrolithiasis with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Sarcoidosis, Pulmonary Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
27 August 2026
Evaluate Sarcoidosis, Pulmonary in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Granular Cell Tumor Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
27 August 2026
Evaluate Granular Cell Tumor with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Demyelinating Diseases Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
27 August 2026
Evaluate Demyelinating Diseases in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Pseudolymphoma Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
27 August 2026
Evaluate Pseudolymphoma with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Hyperparathyroidism Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
27 August 2026
Evaluate Hyperparathyroidism with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Nephrogenic Syndrome of Inappropriate Antidiuresis Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
27 August 2026
Evaluate Nephrogenic Syndrome of in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Infectious Lung Disorder Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
27 August 2026
Evaluate Infectious Lung Disorder in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Salivary Gland Diseases Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
27 August 2026
Evaluate Salivary Gland Diseases in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Fibroma Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
27 August 2026
Evaluate Fibroma with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Hyperparathyroidism 1 Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
27 August 2026
Evaluate Hyperparathyroidism 1 with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap.